Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a research note released on Saturday. The firm issued a sell rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $2.00 target price on shares of Senseonics in a report on Friday.

Senseonics Stock Performance

Shares of NYSE:SENS opened at $0.28 on Friday. The business has a 50 day moving average of $0.35 and a 200-day moving average of $0.40. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 2.47. Senseonics has a 12-month low of $0.28 and a 12-month high of $0.75.

Institutional Investors Weigh In On Senseonics

Hedge funds and other institutional investors have recently made changes to their positions in the business. Mirae Asset Global Investments Co. Ltd. increased its stake in Senseonics by 30.2% during the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 909,931 shares of the company’s stock worth $483,000 after acquiring an additional 211,128 shares during the period. State Board of Administration of Florida Retirement System bought a new stake in Senseonics during the first quarter worth about $91,000. Vanguard Group Inc. grew its stake in Senseonics by 0.7% during the first quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock worth $11,963,000 after buying an additional 155,715 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock worth $196,000 after buying an additional 51,000 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Senseonics in the 1st quarter valued at about $162,000. 12.36% of the stock is currently owned by institutional investors and hedge funds.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.